$25.280
-1.972 (-7.80%)收盘时
ALMR 资讯
ALMR 事件
Alamar Biosciences Publishes Alzheimer's Study
The company states: "Alamar Biosciences announced the publication in The Lancet Neurology of the first longitudinal cohort study to evaluate a broad panel of plasma biomarkers in patients receiving anti-amyloid antibody therapy in real-world clinical practice. The study shows that patients with early symptomatic Alzheimer's disease exhibit markedly different biological responses during treatment with lecanemab. Led by investigators at Washington University School of Medicine in St. Louis, the study used Alamar's NULISAseq(TM) CNS 120 panel to measure 130 plasma proteins spanning amyloid and tau pathology, inflammation, neurodegeneration and synaptic function. Researchers profiled 2,385 samples from 1,967 participants using just 25 microliters of plasma per sample, including patients receiving lecanemab as part of standard clinical care at the Washington University Memory Diagnostic Center and untreated comparison groups from the Knight Alzheimer Disease Research Center."
Alamar Biosciences Stock Rises 15.1% to $36.83
Alamar Biosciences is up 15.1%, or $4.82 to $36.83.
Alamar Biosciences Stock Rises 9.4% to $35.02
Alamar Biosciences is up 9.4%, or $3.01 to $35.02.
Alamar Biosciences Expands Partnership with Alzheimer's Disease Data Initiative
Alamar Biosciences announced an expansion of its strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures. The expanded agreement adds profiling of 86,000 plasma samples using the company's newest neurology panel, NULISAseq Neuro 220. Approximately 21,000 samples are part of a national-scale proteomics initiative launched with leading research universities in mid-July. Building on the June 2025 announcement of a multi-center initiative which profiled over 55,000 samples using Alamar's ultra-sensitive NULISA technology, this expansion reflects growing confidence in the partnership's scientific output and the Neuro 220 panel's ability to deliver richer insights into the co-pathologies driving neurodegenerative disease. The combined dataset, when completed in 2027, is expected to encompass more than 140,000 samples profiled across multiple geographies and cohorts.
Alamar Biosciences Q2 Revenue $29.4M Beats Expectations
Reports Q2 revenue $29.4M, consensus $25.94M. "We delivered a strong second quarter with consumable revenue growing nearly 150% year-over-year," said Yuling Luo, CEO of Alamar Biosciences. "With the recent launches of eMTBR-tau and the Immune 340 Panel strengthening our content menu and extending into new disease areas, we believe we are well-positioned to sustain momentum into the coming quarters."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。